Anticoagulation in Obesity: Rivaroxaban to the Rescue
hosted byConnect Educate Impact (CEI)
Anticoagulation in Obesity: Rivaroxaban to the Rescue is organized by Connect Educate Impact (CEI).
Release Date: March 10, 2021
Expiration Date: March 10, 2024
Description:
Direct-acting oral anticoagulants have emerged as the preferred anticoagulant class for many patients due to their safety profile, efficacy, and ease of use. However, patients with obesity were excluded from the initial clinical trials raising concerns about external validity for this population. Join us to learn the role of rivaroxaban for stroke and venous thromboembolism prevention in patients with obesity.
Objectives:
Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
• Describe the efficacy of rivaroxaban for stroke prevention in atrial fibrillation in patients with obesity
• Describe the efficacy of rivaroxaban for venous thromboembolism prevention in patients with obesity
• Compare the risk of bleeding and hospital length of stay with rivaroxaban versus warfarin in patients with obesity
• Analyze limitations for use of rivaroxaban in patients with obesity
• Develop a conclusion for the clinical appropriateness of care based on a clinical trial.
